Macromolecular Biopharmaceutical Research*

Release time:2023-02-02

On March 29, 2022, Changrui Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as "Changrui Biotechnology

") was awarded the license by Chengdu Tianfu International Biocity, and recognized Changrui Biotechnology as the "public technology platform for carrier drug development and macromolecule biodrug research" in Biocity.

According to the

Measures for the Administration of Innovation Vouchers of Chengdu Tianfu International Bio-City, after Changrui Biotech is recognized as the public technical service platform of the bio-city, enterprises purchasing technical service projects on this platform can use the innovation vouchers issued by Tianfu International Bio-city to deduct up to 50% of the service fee and enjoy the policy dividends of the bio-city.

As the first large-molecule biopharmaceutical CDMO enterprise in western China with new product output capabilities, Changrui Biotech has a development platform for viral vector drugs, nucleic acid drugs, vaccines and recombinant protein drugs, eukaryotic and prokaryotic production sites of 1000-2000 liters, and a perfect quality management system in line with Sino-US double reports. Accelerate the launch of urgently needed clinical drugs.

key words: Macromolecular Biopharmaceutical Research*

relevant